SlideShare a Scribd company logo

Kshivets aats new_york2019

Survival of Esophageal Cancer Patients was Significantly Superior in Comparison with Cardioesophageal Cancer Patients after Surgery Kshivets Oleg Surgery Department, Roshal Hospital, Moscow, Russia OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0) esophagogastrectomies (EG) through left/right thoracoabdominal incision. METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284; esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151; adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199; G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached 51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP – more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP (67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5 days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).

1 of 1
Download to read offline
Survival of Esophageal Cancer Patients was Significantly Superior in
Comparison with Cardioesophageal Cancer Patients after Surgery P39
Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia
OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of
esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0)
esophagogastrectomies (EG) through left/right thoracoabdominal incision.
METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm)
radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284;
esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver,
diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151;
adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199;
G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant
chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox
modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to
determine any significant dependence.
RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached
51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP –
more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP
(67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5
days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank
test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0—
N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells
subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time,
residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm
selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT
early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick
neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC
(10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under
ROC curve=1.0; error=0.0).
CONCLUSIONS: Survival after radical procedures significantly depended on:
1) PT “early—invasive cancer”; 2) PT N0—N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical
factors; 6) hemostasis system; 7) AT; 8) EC characteristics; 9) localization: esophageal cancer—
cardioesophageal cancer; 10) anthropometric data.
Survival Function
General Esophageal Cancer Patients Survival, n=543
5-Year Survival=51.9%; 10-Year Survival=45.7%; 20-Year Survival=33.5%
Complete Censored
-5 0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
CumulativeProportionSurviving
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of Early ECP=100; 5-Year Survival of Invasive ECP=38.5%,
P=0.00000 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
CumulativeProportionSurviving
Invasive ECP, n=436
Early ECP, n=107
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of ECP with N0=73.9%; 5-Year Survival of ECP with N1-2=27.5%
P=0.00000 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
CumulativeProportionSurviving
ECP with N1-2, n=268
ECP with N0, n=275
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of ECP after Adjuvant Treatment=68.2%;
5-Year Survival of ECP after Surgery alone=48.5%;
P=0.00033 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
CumulativeProportionSurviving
Adjuvant Chemoimmunoradiotherapy, n=123
Only Surgery, n=420
Cox Proportional Hazards Results;
ECP/CECP=543;
Factors:
Parameter
Estimate
Standard
Error
Chi-
square
P value
95%
Lower CL
95%
Upper CL
Hazard
Ratio
95%
Hazard
Ratio
Lower CL
95%
Hazard
Ratio
Upper CL
Blood Group 0.24084 0.072842 10.93155 0.000945 0.09807 0.383607 1.272315 1.103040 1.467569
Rh-Factor -0.56749 0.179791 9.96289 0.001597 -0.91988 -0.215110 0.566944 0.398567 0.806453
Hemorrhage Blood 0.00137 0.000411 11.17880 0.000827 0.00057 0.002177 1.001374 1.000568 1.002180
Glucose -0.22903 0.083815 7.46693 0.006284 -0.39330 -0.064756 0.795305 0.674823 0.937296
Residual Nitrogen 0.05126 0.012004 18.23193 0.000020 0.02773 0.074786 1.052594 1.028117 1.077653
Protein 0.02465 0.008997 7.50688 0.006146 0.00702 0.042284 1.024956 1.007041 1.043190
Prothrombin Index 0.01879 0.006672 7.93214 0.004856 0.00571 0.031867 1.018968 1.005730 1.032380
T1-4 0.40958 0.095588 18.35954 0.000018 0.22223 0.596926 1.506179 1.248855 1.816525
N0---N12 0.65015 0.163700 15.77344 0.000071 0.32930 0.970993 1.915823 1.389996 2.640565
Age 0.03171 0.007996 15.72396 0.000073 0.01603 0.047377 1.032214 1.016164 1.048517
Histology -0.34331 0.130570 6.91333 0.008556 -0.59922 -0.087398 0.709419 0.549239 0.916313
G1-3 0.39994 0.089500 19.96816 0.000008 0.22452 0.575354 1.491732 1.251723 1.777760
Adjuvant Chemoimmunoradiotherapy -0.98414 0.202411 23.64005 0.000001 -1.38086 -0.587424 0.373760 0.251362 0.555757
Leucocytes tot -1.40161 0.356959 15.41769 0.000086 -2.10124 -0.701985 0.246200 0.122305 0.495601
Eosinophils tot 1.42230 0.366785 15.03692 0.000105 0.70341 2.141185 4.146644 2.020639 8.509513
Stick Neutrophils tot 1.41661 0.359711 15.50931 0.000082 0.71159 2.121628 4.123112 2.037224 8.344714
Segmented Neutrophils tot 1.42786 0.356560 16.03634 0.000062 0.72901 2.126702 4.169756 2.073034 8.387157
Lymphocytes tot 1.37115 0.358701 14.61190 0.000132 0.66811 2.074194 3.939891 1.950551 7.958130
Monocytes tot 1.31857 0.370179 12.68771 0.000368 0.59303 2.044109 3.738076 1.809469 7.722272
Segmented Neutrophils/Cancer Cells -0.13490 0.045343 8.85118 0.002929 -0.22377 -0.046029 0.873803 0.799498 0.955014
Esophageal Cancer---Cardioesophageal Cancer 0.31674 0.140910 5.05257 0.024589 0.04056 0.592914 1.372640 1.041392 1.809253
Cumulative Proportion Surviving (Kaplan-Meier)
5-Year Survival of ECP=67.3%; 5-Year Survival of CECP=36.4%; P=0.000 by Log-Rank Test
Complete Censored
0 5 10 15 20 25 30 35 40
Years after Esophagogastrectomies
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
CumulativeProportionSurviving
ECP=259
CECP=284
Discriminant Function Analysis Summary:
No. of vars in model=32; n=407
Wilks' Lambda: .39522 approx. F (32,374)=17.885 p<0.0000
Wilks'
Lambda
Partial
Lambda
F-remove
(1,374)
p-value Toler.
1-Toler.
(R-Sqr.)
Hemoglobin 0.405250 0.975248 9.49213 0.002216 0.359799 0.640201
Erythrocytes 0.407808 0.969131 11.91296 0.000621 0.024344 0.975657
Leucocytes 0.413786 0.955129 17.57030 0.000035 0.000405 0.999595
Stick Neutrophils (%) 0.401817 0.983580 6.24345 0.012894 0.081515 0.918486
Segmented Neutrophils (%) 0.412991 0.956969 16.81737 0.000051 0.010315 0.989685
Lymphocytes (%) 0.404156 0.977887 8.45715 0.003853 0.010516 0.989484
Hemorrhage Blood 0.404068 0.978100 8.37382 0.004030 0.843012 0.156988
Residual Nitrogen 0.438737 0.900811 41.18147 0.000000 0.742369 0.257631
Prothrombin Index 0.399773 0.988609 4.30916 0.038590 0.836103 0.163898
Segmented Neutrophils (abs) 0.417926 0.945668 21.48770 0.000005 0.000587 0.999413
Lymphocytes (abs) 0.407544 0.969759 11.66284 0.000708 0.002901 0.997099
T1-4 0.436492 0.905444 39.05685 0.000000 0.541731 0.458269
N0--N12 0.424456 0.931120 27.66664 0.000000 0.704162 0.295838
Weight 0.407512 0.969834 11.63306 0.000719 0.011910 0.988090
G1-3 0.407735 0.969303 11.84421 0.000644 0.835999 0.164001
Tumor Growth 0.407466 0.969943 11.58955 0.000735 0.653263 0.346737
Adjuvant Chemoimmunoradiotherapy 0.400524 0.986755 5.02014 0.025641 0.911147 0.088853
Combined Procedures 0.405038 0.975759 9.29132 0.002466 0.720317 0.279683
Erythrocytes (tot) 0.405575 0.974467 9.79976 0.001883 0.008919 0.991081
Leucocytes (tot) 0.409886 0.964218 13.87926 0.000225 0.000036 0.999964
Eosinophils (tot) 0.405589 0.974434 9.81255 0.001870 0.010102 0.989898
Stick Neutrophils (tot) 0.400922 0.985776 5.39657 0.020712 0.003166 0.996834
Segmented Neutrophils (tot) 0.411970 0.959341 15.85091 0.000082 0.000068 0.999933
Lymphocytes (tot) 0.408867 0.966622 12.91450 0.000370 0.000381 0.999619
Monocytes (tot) 0.407706 0.969373 11.81657 0.000653 0.005423 0.994577
Leucocytes/Cancer Cells 0.401196 0.985102 5.65605 0.017897 0.000009 0.999991
Eosinophils/Cancer Cells 0.401077 0.985396 5.54290 0.019072 0.009880 0.990120
Stick Neutrophils/Cancer Cells 0.401480 0.984406 5.92440 0.015400 0.008813 0.991187
Segmented Neutrophils/Cancer Cells 0.401377 0.984659 5.82676 0.016264 0.000025 0.999975
Lymphocytes/Cancer Cells 0.401133 0.985257 5.59635 0.018507 0.000082 0.999918
Monocytes/Cancer Cells 0.400441 0.986961 4.94101 0.026824 0.001509 0.998491
Localization: EC vs. CEC 0.400283 0.987351 4.79143 0.029219 0.929113 0.070887
Neural Networks: n=407;
Baseline Error=0.000;
Area under ROC Curve=1.000;
Correct Classification Rate=100%
Rank Sensitivity
Healthy Cells/Cancer Cells
Phase Transition Early---Invasive Cancer
Phase Transition N0---N12
Erythrocytes/Cancer Cells
Thrombocytes/Cancer Cells
Stick Neutrophils/Cancer Cells
Lymphocytes/Cancer Cells
Segmented Neutrophils/Cancer Cells
Eosinophils/Cancer Cells
Leucocytes/Cancer Cells
Monocytes/Cancer Cells
1
2
3
4
5
6
7
8
9
10
11
28794
20554
16562
8666
7464
7425
5836
5771
4024
3734
3230
Significant Factors Rank Kendal Tau-A P
Tumor Size 1 -0.316 0.000
Healthy Cells/Cancer Cells 2 0.315 0.000
T1-4 3 -0.307 0.000
Erythrocytes/Cancer Cells 4 0.307 0.000
Leucocytes/Cancer Cells 5 0.298 0.000
Thrombocytes/Cancer Cells 6 0.293 0.000
Lymphocytes/Cancer Cells 7 0.289 0.000
Segmented Neutrophils/Cancer Cells 8 0.280 0.000
Residual Nitrogen 9 -0.277 0.000
Phase Transition N0---N12 10 -0.248 0.000
Monocytes/Cancer Cells 11 0.240 0.000
Hemorrhage Time 12 -0.233 0.000
Phase Transition Early---Invasive Cancer 13 -0.225 0.000
Esophageal---Cardioesophageal Cancer 14 -0.194 0.000
Procedure Type 15 -0.192 0.000
Eosinophils/Cancer Cells 16 0.163 0.000
Chlorides 17 0.163 0.000
G1-3 18 -0.140 0.000
Tumor Growth 19 -0.117 0.001
Stick Neutrophils/Cancer Cells 20 0.105 0.01
Erythrocytes 21 0.103 0.01
Weight 22 0.100 0.01
Combined Procedure 23 0.098 0.01

Recommended

Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets eacts milan2018
Kshivets eacts milan2018Kshivets eacts milan2018
Kshivets eacts milan2018Oleg Kshivets
 
Kshivets astana wscts2017
Kshivets astana wscts2017Kshivets astana wscts2017
Kshivets astana wscts2017Oleg Kshivets
 
Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Kshivets IASLC_Vienna2016
Kshivets IASLC_Vienna2016Oleg Kshivets
 
Kshivets O. Esophageal & Cardioesophageal Cancer Surgery
Kshivets O.  Esophageal & Cardioesophageal Cancer SurgeryKshivets O.  Esophageal & Cardioesophageal Cancer Surgery
Kshivets O. Esophageal & Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets wscts2019 sofia
Kshivets wscts2019 sofiaKshivets wscts2019 sofia
Kshivets wscts2019 sofiaOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets iaslc denver2021
Kshivets iaslc denver2021Kshivets iaslc denver2021
Kshivets iaslc denver2021Oleg Kshivets
 

More Related Content

What's hot

Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016Oleg Kshivets
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaOleg Kshivets
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Oleg Kshivets
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival Oleg Kshivets
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015Oleg Kshivets
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Oleg Kshivets
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisOleg Kshivets
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryOleg Kshivets
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryOleg Kshivets
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Oleg Kshivets
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Oleg Kshivets
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Oleg Kshivets
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019Oleg Kshivets
 

What's hot (20)

Kshivets barcelona2016
Kshivets barcelona2016Kshivets barcelona2016
Kshivets barcelona2016
 
Kshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljanaKshivets wscts2018 ljubljana
Kshivets wscts2018 ljubljana
 
Kshivets sso2013
Kshivets sso2013Kshivets sso2013
Kshivets sso2013
 
Kshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer SurgeryKshivets O. Cardioesophageal Cancer Surgery
Kshivets O. Cardioesophageal Cancer Surgery
 
Kshivets iaslc toronto2018
Kshivets iaslc toronto2018Kshivets iaslc toronto2018
Kshivets iaslc toronto2018
 
Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020Kshivets Hong Kong Sydney2020
Kshivets Hong Kong Sydney2020
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival           Lung Cancer: 10-Year Survival
Lung Cancer: 10-Year Survival
 
Kshivets IASLC 2019
Kshivets IASLC 2019Kshivets IASLC 2019
Kshivets IASLC 2019
 
Kshivets iaslc denver2015
Kshivets iaslc denver2015Kshivets iaslc denver2015
Kshivets iaslc denver2015
 
Kshivets iaslc singapore2020
Kshivets iaslc singapore2020Kshivets iaslc singapore2020
Kshivets iaslc singapore2020
 
Kshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: PrognosisKshivets O. Lung Cancer Surgery: Prognosis
Kshivets O. Lung Cancer Surgery: Prognosis
 
Kshivets wscts2015
Kshivets wscts2015Kshivets wscts2015
Kshivets wscts2015
 
Kshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer SurgeryKshivets O. Lung Cancer Surgery
Kshivets O. Lung Cancer Surgery
 
Kshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer SurgeryKshivets O. Esophagogastric Cancer Surgery
Kshivets O. Esophagogastric Cancer Surgery
 
Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017Kshivets yokohama iaslc2017
Kshivets yokohama iaslc2017
 
Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis Kshivets O. Lung Cancer: Early Detection and Diagnosis
Kshivets O. Lung Cancer: Early Detection and Diagnosis
 
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
Combined Esophagogastrectomies: Survival Outcomes in Patients with Local Adva...
 
Kshivets milan2014
Kshivets milan2014Kshivets milan2014
Kshivets milan2014
 
Kshivets barcelona2019
Kshivets barcelona2019Kshivets barcelona2019
Kshivets barcelona2019
 

Similar to Kshivets aats new_york2019

Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Oleg Kshivets
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryOleg Kshivets
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfOleg Kshivets
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction Oleg Kshivets
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020Oleg Kshivets
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017Oleg Kshivets
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfOleg Kshivets
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Oleg Kshivets
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfOleg Kshivets
 
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...JharkhandOncology
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016Oleg Kshivets
 
Pr Olivier Cussenot
Pr Olivier CussenotPr Olivier Cussenot
Pr Olivier Cussenotall-in-web
 
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療Ks doctor
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Oleg Kshivets
 

Similar to Kshivets aats new_york2019 (20)

Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018Kshivets ASCVTS Moscow2018
Kshivets ASCVTS Moscow2018
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer SurgeryKshivets O. Esophageal and Cardioesophageal Cancer Surgery
Kshivets O. Esophageal and Cardioesophageal Cancer Surgery
 
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues tRNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
 
Kshivets aats new_york2018
Kshivets aats new_york2018Kshivets aats new_york2018
Kshivets aats new_york2018
 
Kshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdfKshivets_SPB_WSCTS2022Eso.pdf
Kshivets_SPB_WSCTS2022Eso.pdf
 
Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction      Esophageal Cancer: Precise Prediction
Esophageal Cancer: Precise Prediction
 
Kshivets barcelona2020
Kshivets barcelona2020Kshivets barcelona2020
Kshivets barcelona2020
 
Kshivets ny2021aats
Kshivets ny2021aatsKshivets ny2021aats
Kshivets ny2021aats
 
Kshivets barcelona2017
Kshivets barcelona2017Kshivets barcelona2017
Kshivets barcelona2017
 
Kshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdfKshivets_SPB_WSCTS2022Lung.pdf
Kshivets_SPB_WSCTS2022Lung.pdf
 
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
Survival of Lung Cancer Patients after Lobectomies was Significantly Superior...
 
Kshivets esmo2021
Kshivets esmo2021Kshivets esmo2021
Kshivets esmo2021
 
KshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdfKshivetsWSCTS2023_Brazil.pdf
KshivetsWSCTS2023_Brazil.pdf
 
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...
LBA26 - BREAKWATER safety lead-in (SLI) Encorafenib (E) + cetuximab (C) + che...
 
Kshivets chicago2016
Kshivets chicago2016Kshivets chicago2016
Kshivets chicago2016
 
Pr Olivier Cussenot
Pr Olivier CussenotPr Olivier Cussenot
Pr Olivier Cussenot
 
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
 
08 Bernat aimradial20170921 Radial patency
08 Bernat aimradial20170921 Radial patency08 Bernat aimradial20170921 Radial patency
08 Bernat aimradial20170921 Radial patency
 
Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020Kshivets ASCO Chicago2020
Kshivets ASCO Chicago2020
 

More from Oleg Kshivets

Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfOleg Kshivets
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfOleg Kshivets
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Oleg Kshivets
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrOleg Kshivets
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021Oleg Kshivets
 

More from Oleg Kshivets (6)

Kshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdfKshivets_IASLC_Singapore2023.pdf
Kshivets_IASLC_Singapore2023.pdf
 
Kshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdfKshivets_WCGIC2023.pdf
Kshivets_WCGIC2023.pdf
 
Kshivets elcc2022
Kshivets elcc2022Kshivets elcc2022
Kshivets elcc2022
 
Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659Kshivets gc 10_ys_wjarr-2021-0659
Kshivets gc 10_ys_wjarr-2021-0659
 
Kshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarrKshivets lc10 ys_wjarr
Kshivets lc10 ys_wjarr
 
Kshivets eso10 y2021
Kshivets eso10 y2021Kshivets eso10 y2021
Kshivets eso10 y2021
 

Recently uploaded

Introduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxIntroduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxMarbahunJalaKharbhih
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxSai Sailesh Kumar Goothy
 
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdf
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdfGuía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdf
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdfJuniorAlexanderCasti
 
Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajMalaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSDr.Shrikrushna Sobaji
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxSizan Thapa
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxYasser Alzainy
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfMedicoseAcademics
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxDr. Dheeraj Kumar
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Golden Helix
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...PeerVoice
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...semualkaira
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJuliethKabirigi1
 
Typhoid.pptx Department of Physiotherapy, SHUATS, Prayagraj
Typhoid.pptx Department of Physiotherapy, SHUATS, PrayagrajTyphoid.pptx Department of Physiotherapy, SHUATS, Prayagraj
Typhoid.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Staphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrStaphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrssuser06f49d
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajSurabhi Srivastava
 
Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxKAUSAR NAHID
 

Recently uploaded (20)

Introduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptxIntroduction to anatomy and physioligy.pptx
Introduction to anatomy and physioligy.pptx
 
Physiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptxPhysiology of Pituitary gland and its hormones -3.pptx
Physiology of Pituitary gland and its hormones -3.pptx
 
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdf
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdfGuía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdf
Guía síndrome coronario agudo.pdf Guía síndrome coronario agudo.pdf
 
Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, PrayagrajMalaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
Malaria Disease.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICSPAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
PAEDIATRICS RHEMATOLOGY PROTOCOLS SHEET FOR PEDIATRICS ORTHOPAEDICS
 
Hydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptxHydrocele and tumors of testis Introduction.pptx
Hydrocele and tumors of testis Introduction.pptx
 
Vertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptxVertigo and Nystagmus - Clinical approach part-2.pptx
Vertigo and Nystagmus - Clinical approach part-2.pptx
 
Fetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdfFetal and Neonatal Physiology - Dr Faiza.pdf
Fetal and Neonatal Physiology - Dr Faiza.pdf
 
Population of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptxPopulation of India and Family welfare programme.pptx
Population of India and Family welfare programme.pptx
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
 
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
(DENGUE).pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
 
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
Bedside Utility of Liaoning Score a Non-Invasive As Predictor of Esophageal V...
 
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHASJULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
JULIETH KABIRIGI,PAED.CARDIOLOGIST-CUHAS
 
Typhoid.pptx Department of Physiotherapy, SHUATS, Prayagraj
Typhoid.pptx Department of Physiotherapy, SHUATS, PrayagrajTyphoid.pptx Department of Physiotherapy, SHUATS, Prayagraj
Typhoid.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, PrayagrajMeasles.pptx Department of Physiotherapy, SHUATS, Prayagraj
Measles.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
Staphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badrStaphylococcus.ppt.........ali.rasool.badr
Staphylococcus.ppt.........ali.rasool.badr
 
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, PrayagrajPoliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
Poliomyelitis.pptx Department of Physiotherapy, SHUATS, Prayagraj
 
A rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid TorsionA rare case of Omental & Fibroid Torsion
A rare case of Omental & Fibroid Torsion
 
Materials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptxMaterials for Spectacle Lenses​ UG STUDENTS.pptx
Materials for Spectacle Lenses​ UG STUDENTS.pptx
 

Kshivets aats new_york2019

  • 1. Survival of Esophageal Cancer Patients was Significantly Superior in Comparison with Cardioesophageal Cancer Patients after Surgery P39 Oleg Kshivets, MD, PhD Surgery Department, Roshal Hospital, Roshal, Moscow, Russia OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0) esophagogastrectomies (EG) through left/right thoracoabdominal incision. METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284; esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151; adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199; G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached 51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP – more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP (67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5 days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0— N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: Survival after radical procedures significantly depended on: 1) PT “early—invasive cancer”; 2) PT N0—N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) EC characteristics; 9) localization: esophageal cancer— cardioesophageal cancer; 10) anthropometric data. Survival Function General Esophageal Cancer Patients Survival, n=543 5-Year Survival=51.9%; 10-Year Survival=45.7%; 20-Year Survival=33.5% Complete Censored -5 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of Early ECP=100; 5-Year Survival of Invasive ECP=38.5%, P=0.00000 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving Invasive ECP, n=436 Early ECP, n=107 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of ECP with N0=73.9%; 5-Year Survival of ECP with N1-2=27.5% P=0.00000 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving ECP with N1-2, n=268 ECP with N0, n=275 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of ECP after Adjuvant Treatment=68.2%; 5-Year Survival of ECP after Surgery alone=48.5%; P=0.00033 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving Adjuvant Chemoimmunoradiotherapy, n=123 Only Surgery, n=420 Cox Proportional Hazards Results; ECP/CECP=543; Factors: Parameter Estimate Standard Error Chi- square P value 95% Lower CL 95% Upper CL Hazard Ratio 95% Hazard Ratio Lower CL 95% Hazard Ratio Upper CL Blood Group 0.24084 0.072842 10.93155 0.000945 0.09807 0.383607 1.272315 1.103040 1.467569 Rh-Factor -0.56749 0.179791 9.96289 0.001597 -0.91988 -0.215110 0.566944 0.398567 0.806453 Hemorrhage Blood 0.00137 0.000411 11.17880 0.000827 0.00057 0.002177 1.001374 1.000568 1.002180 Glucose -0.22903 0.083815 7.46693 0.006284 -0.39330 -0.064756 0.795305 0.674823 0.937296 Residual Nitrogen 0.05126 0.012004 18.23193 0.000020 0.02773 0.074786 1.052594 1.028117 1.077653 Protein 0.02465 0.008997 7.50688 0.006146 0.00702 0.042284 1.024956 1.007041 1.043190 Prothrombin Index 0.01879 0.006672 7.93214 0.004856 0.00571 0.031867 1.018968 1.005730 1.032380 T1-4 0.40958 0.095588 18.35954 0.000018 0.22223 0.596926 1.506179 1.248855 1.816525 N0---N12 0.65015 0.163700 15.77344 0.000071 0.32930 0.970993 1.915823 1.389996 2.640565 Age 0.03171 0.007996 15.72396 0.000073 0.01603 0.047377 1.032214 1.016164 1.048517 Histology -0.34331 0.130570 6.91333 0.008556 -0.59922 -0.087398 0.709419 0.549239 0.916313 G1-3 0.39994 0.089500 19.96816 0.000008 0.22452 0.575354 1.491732 1.251723 1.777760 Adjuvant Chemoimmunoradiotherapy -0.98414 0.202411 23.64005 0.000001 -1.38086 -0.587424 0.373760 0.251362 0.555757 Leucocytes tot -1.40161 0.356959 15.41769 0.000086 -2.10124 -0.701985 0.246200 0.122305 0.495601 Eosinophils tot 1.42230 0.366785 15.03692 0.000105 0.70341 2.141185 4.146644 2.020639 8.509513 Stick Neutrophils tot 1.41661 0.359711 15.50931 0.000082 0.71159 2.121628 4.123112 2.037224 8.344714 Segmented Neutrophils tot 1.42786 0.356560 16.03634 0.000062 0.72901 2.126702 4.169756 2.073034 8.387157 Lymphocytes tot 1.37115 0.358701 14.61190 0.000132 0.66811 2.074194 3.939891 1.950551 7.958130 Monocytes tot 1.31857 0.370179 12.68771 0.000368 0.59303 2.044109 3.738076 1.809469 7.722272 Segmented Neutrophils/Cancer Cells -0.13490 0.045343 8.85118 0.002929 -0.22377 -0.046029 0.873803 0.799498 0.955014 Esophageal Cancer---Cardioesophageal Cancer 0.31674 0.140910 5.05257 0.024589 0.04056 0.592914 1.372640 1.041392 1.809253 Cumulative Proportion Surviving (Kaplan-Meier) 5-Year Survival of ECP=67.3%; 5-Year Survival of CECP=36.4%; P=0.000 by Log-Rank Test Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomies 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 CumulativeProportionSurviving ECP=259 CECP=284 Discriminant Function Analysis Summary: No. of vars in model=32; n=407 Wilks' Lambda: .39522 approx. F (32,374)=17.885 p<0.0000 Wilks' Lambda Partial Lambda F-remove (1,374) p-value Toler. 1-Toler. (R-Sqr.) Hemoglobin 0.405250 0.975248 9.49213 0.002216 0.359799 0.640201 Erythrocytes 0.407808 0.969131 11.91296 0.000621 0.024344 0.975657 Leucocytes 0.413786 0.955129 17.57030 0.000035 0.000405 0.999595 Stick Neutrophils (%) 0.401817 0.983580 6.24345 0.012894 0.081515 0.918486 Segmented Neutrophils (%) 0.412991 0.956969 16.81737 0.000051 0.010315 0.989685 Lymphocytes (%) 0.404156 0.977887 8.45715 0.003853 0.010516 0.989484 Hemorrhage Blood 0.404068 0.978100 8.37382 0.004030 0.843012 0.156988 Residual Nitrogen 0.438737 0.900811 41.18147 0.000000 0.742369 0.257631 Prothrombin Index 0.399773 0.988609 4.30916 0.038590 0.836103 0.163898 Segmented Neutrophils (abs) 0.417926 0.945668 21.48770 0.000005 0.000587 0.999413 Lymphocytes (abs) 0.407544 0.969759 11.66284 0.000708 0.002901 0.997099 T1-4 0.436492 0.905444 39.05685 0.000000 0.541731 0.458269 N0--N12 0.424456 0.931120 27.66664 0.000000 0.704162 0.295838 Weight 0.407512 0.969834 11.63306 0.000719 0.011910 0.988090 G1-3 0.407735 0.969303 11.84421 0.000644 0.835999 0.164001 Tumor Growth 0.407466 0.969943 11.58955 0.000735 0.653263 0.346737 Adjuvant Chemoimmunoradiotherapy 0.400524 0.986755 5.02014 0.025641 0.911147 0.088853 Combined Procedures 0.405038 0.975759 9.29132 0.002466 0.720317 0.279683 Erythrocytes (tot) 0.405575 0.974467 9.79976 0.001883 0.008919 0.991081 Leucocytes (tot) 0.409886 0.964218 13.87926 0.000225 0.000036 0.999964 Eosinophils (tot) 0.405589 0.974434 9.81255 0.001870 0.010102 0.989898 Stick Neutrophils (tot) 0.400922 0.985776 5.39657 0.020712 0.003166 0.996834 Segmented Neutrophils (tot) 0.411970 0.959341 15.85091 0.000082 0.000068 0.999933 Lymphocytes (tot) 0.408867 0.966622 12.91450 0.000370 0.000381 0.999619 Monocytes (tot) 0.407706 0.969373 11.81657 0.000653 0.005423 0.994577 Leucocytes/Cancer Cells 0.401196 0.985102 5.65605 0.017897 0.000009 0.999991 Eosinophils/Cancer Cells 0.401077 0.985396 5.54290 0.019072 0.009880 0.990120 Stick Neutrophils/Cancer Cells 0.401480 0.984406 5.92440 0.015400 0.008813 0.991187 Segmented Neutrophils/Cancer Cells 0.401377 0.984659 5.82676 0.016264 0.000025 0.999975 Lymphocytes/Cancer Cells 0.401133 0.985257 5.59635 0.018507 0.000082 0.999918 Monocytes/Cancer Cells 0.400441 0.986961 4.94101 0.026824 0.001509 0.998491 Localization: EC vs. CEC 0.400283 0.987351 4.79143 0.029219 0.929113 0.070887 Neural Networks: n=407; Baseline Error=0.000; Area under ROC Curve=1.000; Correct Classification Rate=100% Rank Sensitivity Healthy Cells/Cancer Cells Phase Transition Early---Invasive Cancer Phase Transition N0---N12 Erythrocytes/Cancer Cells Thrombocytes/Cancer Cells Stick Neutrophils/Cancer Cells Lymphocytes/Cancer Cells Segmented Neutrophils/Cancer Cells Eosinophils/Cancer Cells Leucocytes/Cancer Cells Monocytes/Cancer Cells 1 2 3 4 5 6 7 8 9 10 11 28794 20554 16562 8666 7464 7425 5836 5771 4024 3734 3230 Significant Factors Rank Kendal Tau-A P Tumor Size 1 -0.316 0.000 Healthy Cells/Cancer Cells 2 0.315 0.000 T1-4 3 -0.307 0.000 Erythrocytes/Cancer Cells 4 0.307 0.000 Leucocytes/Cancer Cells 5 0.298 0.000 Thrombocytes/Cancer Cells 6 0.293 0.000 Lymphocytes/Cancer Cells 7 0.289 0.000 Segmented Neutrophils/Cancer Cells 8 0.280 0.000 Residual Nitrogen 9 -0.277 0.000 Phase Transition N0---N12 10 -0.248 0.000 Monocytes/Cancer Cells 11 0.240 0.000 Hemorrhage Time 12 -0.233 0.000 Phase Transition Early---Invasive Cancer 13 -0.225 0.000 Esophageal---Cardioesophageal Cancer 14 -0.194 0.000 Procedure Type 15 -0.192 0.000 Eosinophils/Cancer Cells 16 0.163 0.000 Chlorides 17 0.163 0.000 G1-3 18 -0.140 0.000 Tumor Growth 19 -0.117 0.001 Stick Neutrophils/Cancer Cells 20 0.105 0.01 Erythrocytes 21 0.103 0.01 Weight 22 0.100 0.01 Combined Procedure 23 0.098 0.01